FALLS CHURCH, Va., July 14 /PRNewswire-FirstCall/ -- CSC announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to establish and operate a Phase 1 clinical trial unit for infectious disease therapeutics.
The contract is valued at approximately $32.3 million over a seven-year period. DVC is teaming with Quintiles Transnational Corp. to complete this work.
Under the terms of the agreement, DVC and Quintiles will manage a Phase 1 clinical trial unit to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year. As the prime contractor, DVC will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Quintiles will provide Phase 1 clinical research and support services for the implementation and conduct of approved Phase 1 clinical trial protocols.
Trials will include therapeutic candidates for a broad range of infectious diseases. Investigational products tested could include measures to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
"DVC and Quintiles have an established history of success -- both individually and as partners -- in clinical trial management of medical countermeasures," said Dr. Robert V. House, president of DVC. "DVC has successfully advanced eight products into clinical trials in the last 10 years. This represents an expansion of DVC's capabilities in pharmaceutical product development."
"Quintiles is pleased to expand our existing government contracting relationship with DVC," said Oren Cohen, M.D., senior vice president and managing director of Quintiles' Public Health and Government Services business. "Quintiles' portion of the work on this contract will take place in our new, state-of-the-art, 150-bed Phase 1 clinical research unit in Overland Park, Kan. The facility was dedicated in May 2007 and provides an ideal setting to perform multiple, concurrent clinical trials."
Work will be performed by DVC at its headquarters in Frederick, Md.
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, commercialization and strategic partnering for the pharmaceutical, biotechnology and medical device industries. With more than 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com.
DynPort Vaccine Company LLC (DVC) manages product development programs and provides consulting, technical and program management services to U.S. government agencies and companies in the biotechnology and pharmaceutical industries. For more information, visit http://www.csc.com/dvc. DVC is part of CSC's North American Public Sector business unit's Government Health Services Division. CSC's expertise in providing health services to government agencies has grown over the last five decades to offer commercial best practices integrated to meet federal, state and local healthcare requirements. Services range from optimizing claims processing to operating disease surveillance systems to vaccine development and management. CSC's ideas and solutions are improving the quality of healthcare with better information for better decisions to save lives and money.
CSC is a leading information technology (IT) services company. CSC's mission is to be a global leader in providing technology-enabled business solutions and services.
With approximately 90,000 employees, CSC provides innovative solutions for customers around the world by applying leading technologies and CSC's own advanced capabilities. These include systems design and integration; IT and business process outsourcing; applications software development; Web and application hosting; and management consulting. Headquartered in Falls Church, Va., CSC reported revenue of $16.5 billion for the 12 months ended March 28, 2008. For more information, visit the company's Web site at http://www.csc.com.
This project has been funded in whole or in part with Federal (United States Government) funds from the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases (DMID), under contract number HHSN272200800024C. Pursuant to section 507 of P.L. 104-208 and Section 508 of P.L. 105-78, 100% of the total of this project's costs are financed with Federal funds. The content of this publication does not necessarily reflect the views or policies of the United States Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
CONTACT: April Finnen, Senior Manager, Communications of DynPort Vaccine
Company LLC, +1-301-607-5004, email@example.com, or Bill Lackey, Director,
Investor Relations, Corporate of CSC, +1-310-615-1700, firstname.lastname@example.org
Web site: http://www.csc.com/